Benzinga | Jan 21, 2022 06:57AM EST

B of A Securities Upgrades Inovio Pharmaceuticals to Neutral, Raises Price Target to $10

B of A Securities analyst Geoff Meacham upgrades Inovio Pharmaceuticals (NASDAQ:INO) from Underperform to Neutral and raises the price target from $8 to $10.